Skip to main content
Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study.
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.
'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
Neurological symptoms in individuals with fibrodysplasia ossificans progressiva.
CNS demyelination in fibrodysplasia ossificans progressiva.
Clinical predictors of early second event in patients with clinically isolated syndrome.